LENVIMA® (lenvatinib) is indicated:
Differentiated Thyroid Cancer (DTC)
For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC

Renal Cell Carcinoma (RCC)
In combination with pembrolizumab, for the first-line treatment of adult patients with advanced RCC
In combination with everolimus, for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy

Hepatocellular Carcinoma (HCC)

For the first-line treatment of patients with unresectable HCC
Endometrial Carcinoma (EC)

In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation